JP2019511553A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511553A5 JP2019511553A5 JP2018554360A JP2018554360A JP2019511553A5 JP 2019511553 A5 JP2019511553 A5 JP 2019511553A5 JP 2018554360 A JP2018554360 A JP 2018554360A JP 2018554360 A JP2018554360 A JP 2018554360A JP 2019511553 A5 JP2019511553 A5 JP 2019511553A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- inhibitor
- composition according
- dyrk1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323583P | 2016-04-15 | 2016-04-15 | |
| US62/323,583 | 2016-04-15 | ||
| PCT/US2017/027734 WO2017181087A1 (en) | 2016-04-15 | 2017-04-14 | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511553A JP2019511553A (ja) | 2019-04-25 |
| JP2019511553A5 true JP2019511553A5 (OSRAM) | 2020-06-11 |
| JP7278776B2 JP7278776B2 (ja) | 2023-05-22 |
Family
ID=60039311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554360A Active JP7278776B2 (ja) | 2016-04-15 | 2017-04-14 | 静止細胞標的化および有糸分裂の阻害剤を用いた新生物の処置のための組み合わせ |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10314843B2 (OSRAM) |
| EP (1) | EP3443351A4 (OSRAM) |
| JP (1) | JP7278776B2 (OSRAM) |
| KR (2) | KR20230020560A (OSRAM) |
| CN (1) | CN109313197A (OSRAM) |
| AU (2) | AU2017248807A1 (OSRAM) |
| BR (1) | BR112018071023A2 (OSRAM) |
| CA (1) | CA3020978A1 (OSRAM) |
| IL (2) | IL292475A (OSRAM) |
| MX (2) | MX2018012508A (OSRAM) |
| WO (1) | WO2017181087A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109562176A (zh) | 2016-04-15 | 2019-04-02 | 费利克斯疗法公司 | 使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合 |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20150104T1 (xx) * | 2009-09-11 | 2015-03-13 | Amgen, Inc. | N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(4-metil-2-thienil)-1-ftalazinamin za primjenu u tretmanu kancera rezistentnog na antimitotiäśke agense |
| US20120184562A1 (en) | 2011-01-19 | 2012-07-19 | Kin-Chun Luk | 1,6- and 1,8-naphthyridines |
| PL2744797T3 (pl) * | 2011-08-19 | 2016-01-29 | Diaxonhit | Inhibitory dyrk1 i ich zastosowanie |
| FR2993317B1 (fr) | 2012-07-16 | 2014-08-15 | Snecma | Carter de turbomachine dans un materiau composite et procede de fabrication associe |
| US20150292032A1 (en) * | 2012-10-10 | 2015-10-15 | Felicitex Therapeutics, Inc. | Treatment of cancer by targeting quiescent cancer cells |
| EP3007692A1 (en) * | 2013-06-11 | 2016-04-20 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor |
| CA2854542A1 (en) * | 2013-06-18 | 2014-12-18 | 4Sc Discovery Gmbh | Method of inhibiting dyrk1b |
| US9566280B2 (en) * | 2014-01-28 | 2017-02-14 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
| PE20170127A1 (es) * | 2014-03-20 | 2017-03-30 | Samumed Llc | Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas |
| US20170304313A1 (en) | 2014-10-06 | 2017-10-26 | Novartis Ag | Therapeutic Combination For The Treatment Of Cancer |
| CN108135871B (zh) * | 2015-07-23 | 2022-11-04 | 博蔚医药生物科技股份有限公司 | 阻断疾病的泛素化-蛋白酶体系统的胺萘醌化合物及医药组合物 |
| CN109562176A (zh) | 2016-04-15 | 2019-04-02 | 费利克斯疗法公司 | 使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合 |
-
2017
- 2017-04-14 BR BR112018071023A patent/BR112018071023A2/pt not_active Application Discontinuation
- 2017-04-14 IL IL292475A patent/IL292475A/en unknown
- 2017-04-14 US US15/488,143 patent/US10314843B2/en active Active
- 2017-04-14 WO PCT/US2017/027734 patent/WO2017181087A1/en not_active Ceased
- 2017-04-14 CN CN201780037724.5A patent/CN109313197A/zh active Pending
- 2017-04-14 CA CA3020978A patent/CA3020978A1/en active Pending
- 2017-04-14 JP JP2018554360A patent/JP7278776B2/ja active Active
- 2017-04-14 EP EP17783296.1A patent/EP3443351A4/en not_active Withdrawn
- 2017-04-14 KR KR1020237002817A patent/KR20230020560A/ko not_active Ceased
- 2017-04-14 AU AU2017248807A patent/AU2017248807A1/en not_active Abandoned
- 2017-04-14 MX MX2018012508A patent/MX2018012508A/es unknown
- 2017-04-14 KR KR1020187033030A patent/KR102494172B1/ko active Active
-
2018
- 2018-10-11 IL IL262325A patent/IL262325B/en unknown
- 2018-10-12 MX MX2022012146A patent/MX2022012146A/es unknown
-
2019
- 2019-06-10 US US16/436,305 patent/US20190290651A1/en not_active Abandoned
-
2021
- 2021-12-21 US US17/558,204 patent/US20220110941A1/en not_active Abandoned
-
2023
- 2023-08-08 AU AU2023214240A patent/AU2023214240A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL292475A (en) | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis | |
| JP2019511554A5 (OSRAM) | ||
| JP2010526098A5 (OSRAM) | ||
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| JP2020529993A5 (OSRAM) | ||
| JP2015528812A5 (OSRAM) | ||
| JP2010526097A5 (OSRAM) | ||
| PH12017500276A1 (en) | Aminopyrimidinyl compounds as jak inhibitors | |
| TR201905814T4 (tr) | Jak inhibitörü olarak bipirazol tuzu. | |
| JP2014176384A5 (OSRAM) | ||
| EA201490357A1 (ru) | Индазолы | |
| NZ626942A (en) | New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same | |
| JP2021501208A5 (OSRAM) | ||
| CL2013003073A1 (es) | Compuestos derivados de pirrolotriazinona o imidazotriazinona, inhibidores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; utiles en el tratamiento de enfermedades respiratorias, inflamatorias, autoinmune, neurologica, cancer, entre otras. | |
| MY155639A (en) | 2, 6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors | |
| AR037032A1 (es) | Benzoimidazoles | |
| NZ721617A (en) | Heterocyclic compounds | |
| TN2018000119A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
| PE20130246A1 (es) | COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SINTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO | |
| EA201390736A1 (ru) | Циклобутилзамещенные производные пирролопиридина и пирролопиримидина как ингибиторы jak | |
| EA201890094A1 (ru) | Производные полициклических амидов в качестве ингибиторов cdk9 | |
| EA201270339A1 (ru) | Замещенные производные ксантина | |
| RU2020115581A (ru) | Фармацевтическая композиция для предупреждения или лечения острого миелоидного лейкоза или метастатического рака молочной железы | |
| PH12017500564B1 (en) | Novel imidazopyridazine compounds and their use | |
| EA201790603A1 (ru) | Ингибиторы гистондеметилазы |